scispace - formally typeset
J

Jonathan L. Bramson

Researcher at McMaster University

Publications -  182
Citations -  8060

Jonathan L. Bramson is an academic researcher from McMaster University. The author has contributed to research in topics: Cytotoxic T cell & T cell. The author has an hindex of 48, co-authored 170 publications receiving 7264 citations. Previous affiliations of Jonathan L. Bramson include Jewish General Hospital & McMaster-Carr.

Papers
More filters
Journal ArticleDOI

Interactions Between the Immune System and Cancer: A Brief Review of Non-spatial Mathematical Models

TL;DR: The simplest (single equation) models for tumor growth and greater immunological detail are considered and the necessity for expanding the complexity of models in order to capture the biological mechanisms the authors wish to understand is clarified.
Journal ArticleDOI

Direct Intratumoral Injection of an Adenovirus Expressing Interleukin-12 Induces Regression and Long-Lasting Immunity That Is Associated with Highly Localized Expression of Interleukin-12

TL;DR: AdmIL-12.1 can be used to deliver very high levels of localized cytokine production and it is confirmed that the IL-12 produced from this vector actually affects the local cytokine environment of the tumor and activates responder cells present within the tumor.
Journal ArticleDOI

TNF-α is a critical negative regulator of type 1 immune activation during intracellular bacterial infection

TL;DR: TNF-alpha is identified as a type 1 immunoregulatory cytokine whose primary role, different from those of other type 1 cytokines, is to keep an otherwise detrimental type 1 immune response in check.
Journal ArticleDOI

Blood CD33(+)HLA-DR(−) myeloid-derived suppressor cells are increased with age and a history of cancer

TL;DR: This analysis is the first to demonstrate that MDSCs and specifically the CD11b(+)CD15(+) MDSC subset are increased with age, and this age‐related elevation in the frequency of M DSCs may contribute to the increased cancer incidence that occurs with age.
Journal Article

IL-12 gene therapy protects mice in lethal Klebsiella pneumonia.

TL;DR: Ex vivo transfection with Ad5mIL-12 resulted in 45% long term survival in Klebsiella pneumonia, whereas no animals with Klebsialla pneumonia receiving control adenovirus survived, and treatment with anti-IFN-gamma Abs or soluble TNF receptor:Ig construct partially and completely attenuated survival benefits observed in animals receiving Ad5MIL- 12, respectively.